Technology
Health
Pharmaceutical

Medicines Company

$26.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.18 (0.68%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MDCO and other stocks, options, ETFs, and crypto commission-free!

About

Medicines Company (The) Common Stock, also called Medicines Company, is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. Read More The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ.

Employees
62
Headquarters
Parsippany, New Jersey
Founded
1996
Market Cap
1.96B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
996.53K
High Today
$26.97
Low Today
$26.15
Open Price
$26.54
Volume
173.52K
52 Week High
$41.57
52 Week Low
$16.69

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Healthcare
US
North America

News

TradingNewsNowMar 22

Present Performance: The Medicines Company (NASDAQ: MDCO)

The Medicines Company is in the drug manufacturers industry and is part of the healthcare sector. The company CEO is Mark Timney. The Medicines Co is a pharmaceutical company. It provides transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers. The company’s products are Angiomax, Ionsys, Minocin for injection and Orbactiv. Previous Intraday Trading Performance: The MDCO stock showed a previous change of 3.59% with an open at 27.58 and a close of ...

19
Associated PressMar 13

Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results

~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from Prior Quarter ~ ~ Corporate Milestones Across Commercial Operations, Clinical and Business Development Provide Critical Growth Opportunities ~ ~ Provides Guidance for 2019 ~ MORRISTOWN, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and ...

32
Simply Wall StMar 11

Will The Medicines Company’s (NASDAQ:MDCO) Earnings Grow In The Next Couple Of Years?

The latest earnings announcement The Medicines Company (NASDAQ:MDCO) released in December 2018 confirmed that losses became smaller relative to the prior year’s level as a result of recent tailwinds Below is my commentary, albeit very simple and high-level, on how market analysts perceive Medicines’s earnings growth trajectory over the next few years and whether the future looks brighter.

52

Earnings

-$1.96
-$1.49
-$1.02
-$0.55
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 24, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.